Outcomes of CAG Regimen for Refractory Biphenotypic Acute Leukemia Patients

Guang-sheng He; Xiang Zhang; De-pei Wu; Ai-ning Sun; Zheng-ming Jin; Hui-ying Qiu; Miao Miao; Xiao-wen Tang; Zheng-zheng Fu; and Yue Han Jiangsu Insititute of Hematology; the First Affiliated Hospital of Soochow University; Thrombosis and Hemostasis Key Laboratory of Ministry of Health of Soochow University; Suzhou 215006; China

Your Location：

Home >

Browse articles >

Outcomes of CAG Regimen for Refractory Biphenotypic Acute Leukemia Patients

中国医学科学杂志（英文版） 2009年24卷第3期页码：178-181

Updated：2024-04-10

- Outcomes of CAG Regimen for Refractory Biphenotypic Acute Leukemia Patients
- Affiliations：
- Author bio：
- Funds：
  
  Supported by the Development of Society Foundation of Suzhou （SS0813）;the Natural Science Foundation of Jiangsu Province （2004BK424）;the 135 Key Department Foundation of Jiangsu Province （135XY0416）;the Outstanding Person Fund the Jiangsu Province （LJ200626）;the Outstanding Person Fund of the First Affiliated Hospital of Soochow University （2004YQG05）
- DOI：
  中图分类号： R733.7
- 纸质出版日期：2009
- Accepted：
Scan QR Code
[1].Outcomes of CAG Regimen for Refractory Biphenotypic Acute Leukemia Patients[J].Chinese Medical Sciences Journal,2009,24(03):178-181.

Guang-sheng He, Xiang Zhang, De-pei Wu, et al. Outcomes of CAG Regimen for Refractory Biphenotypic Acute Leukemia Patients[J]. Chinese medical sciences journal, 2009, 24(3): 178-181.
[1].Outcomes of CAG Regimen for Refractory Biphenotypic Acute Leukemia Patients[J].Chinese Medical Sciences Journal,2009,24(03):178-181. DOI：

Guang-sheng He, Xiang Zhang, De-pei Wu, et al. Outcomes of CAG Regimen for Refractory Biphenotypic Acute Leukemia Patients[J]. Chinese medical sciences journal, 2009, 24(3): 178-181. DOI：

摘要

Objective To evaluated the efficiency of low-dose cytosine arabinoside plus aclarubicin with concurrent administration of granulocyte colony-stimulating factor （CAG） regimen for refractory biphenotypic acute leukemia （BAL）. Methods We treated 5 refractory BAL patients by CAG regimen （10 mg·m-2 cytosine arabinoside subcutaneously administrated every 12 hours

day 1-14; 5-7 mg·m-2 aclarubicin intravenously administrated daily

day 1-8; and concurrently used 200μg·m-2·d-1 granulocyte colony-stimulating factor subcutaneously） from November 2002 to April 2007. The efficacy of the regimen was evaluated by response rate

and the side effects were also measured. Results The complete remission rate was 80%

median duration of absolute neutrophil count< 5.0×108/L and platelet count<2.0×1010/L was day 13 and day 1

respectively; and the infection rate was low （Ⅲ-Ⅳ infection rate

20.00%）. Conclusion CAG regimen as remission induction chemotherapy for BAL patients is effective with a high remission rate and low toxicity.

Abstract

day 1-14; 5-7 mg·m-2 aclarubicin intravenously administrated daily

day 1-8; and concurrently used 200μg·m-2·d-1 granulocyte colony-stimulating factor subcutaneously） from November 2002 to April 2007. The efficacy of the regimen was evaluated by response rate

and the side effects were also measured. Results The complete remission rate was 80%

median duration of absolute neutrophil count< 5.0×108/L and platelet count<2.0×1010/L was day 13 and day 1

respectively; and the infection rate was low （Ⅲ-Ⅳ infection rate

20.00%）. Conclusion CAG regimen as remission induction chemotherapy for BAL patients is effective with a high remission rate and low toxicity.

关键词

Keywords

references

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

关联资源

暂无数据